医学
腺鳞癌
腺癌
粘液表皮样癌
癌
阶段(地层学)
肺
入射(几何)
大细胞
内科学
淋巴结
肿瘤科
癌症
外科
古生物学
物理
光学
生物
作者
Michael Abele,Viera Bajčiová,Fiona Wright,Sam Behjati,Sarah Voggel,Dominik T. Schneider,Coralie Mallebranche,Maja Česen,Gabriela Guillén,Małgorzata Krawczyk,Ewa Bień,Jelena Roganović,Gianni Bisogno,Stefano Chiaravalli,Andrea Ferrari,Ines B. Brecht,Daniel Orbach,Yves Réguerre,Calogero Virgone
标识
DOI:10.1016/j.ejca.2022.08.007
摘要
Primary lung carcinoma is an exceptionally rare childhood tumour, as per definition of the European Cooperative Study Group on Paediatric Rare Tumours (EXPeRT), with an incidence of 0.1-0.2/1,000,000 per year. Little is known about the clinical characteristics of children with primary lung carcinoma, a gap which this joint analysis of the EXPeRT group aimed to fill.We performed a retrospective case series of children (aged 0-18 years) with primary lung carcinoma, as collected through the EXPeRT databases between 2000 and 2021. We recorded relevant clinical characteristics including treatment and outcome.Thirty-eight patients were identified with a median age of 12.8 years at diagnosis (range: 0-17). Mucoepidermoid carcinoma (MEC) was the most frequent entity (n = 20), followed by adenocarcinoma (n = 12), squamous cell carcinoma (n = 4), adenosquamous carcinoma (n = 1) and small-cell lung cancer (n = 1). Patients with MEC presented rarely with lymph node metastases (2/20 cases). Overall, 19/20 patients achieved long-lasting remission by surgical resection only. Patients with other histologies often presented in advanced stages (14/18 TNM stage IV). With multimodal treatment, 3-year overall survival was 52% ± 13%. While all patients with squamous cell carcinoma died, the 12 patients with adenocarcinoma had a 3-year overall survival of 64% ± 15%.Primary lung carcinomas rarely occur in children. While the outcome of children with MEC is favourable with surgery alone, patients with other histotypes have a poor prognosis, despite aggressive treatment, highlighting the need to develop new strategies for these children, such as mutation-guided treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI